Alpha Mannosidosis Market Report 2026

Alpha Mannosidosis Market Overview

• Alpha Mannosidosis market size has reached to $17.87 billion in 2025 • Expected to grow to $39.41 billion in 2030 at a compound annual growth rate (CAGR) of 17% • Growth Driver: Harnessing Precision Medicine Fueling Growth In The Alpha-Mannosidosis Market Through Tailored Treatments • Market Trend: Focus On Enzyme Replacement Therapy Drives Innovation In The Alpha Mannosidosis Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alpha Mannosidosis Market?

Alpha mannosidosis refers to a rare genetic disorder defined by the body's cells' inability to adequately break down specific groups of complex sugars. Numerous bodily organs and systems, including the central nervous system, are impacted by sugar buildup. The disease's effects might vary greatly from person to person. The main types of therapy for alpha mannosidosis are bone marrow transplant (BMT), enzyme replacement therapy (ERT), and others. A bone marrow transplant is a procedure in which dysfunctional marrow is replaced with healthy marrow. Enzyme replacement therapy includes replacing a defective enzyme in people who are lacking or deficient in that enzyme. The different types of indications include Type I, Type II, and Type III and are implemented in a wide range of verticals such as hospitals and specialty clinics.

What Is The Alpha Mannosidosis Market Growth Forecast?

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $39.41 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to increased investment in gene therapies, growing adoption of enzyme replacement therapies, expansion of healthcare infrastructure, technological advancements in diagnostics, regulatory incentives for rare diseases. Major trends in the forecast period include early genetic screening programs, development of orphan drugs, personalized enzyme replacement therapy, expansion of rare disease clinics, collaborative research initiatives.

Global Alpha Mannosidosis Market Segmentation

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies 2) By Indication: Type I, Type II, Type III 3) By End-User: Hospitals, Speciality Clinics Subsegments: 1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT 2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations 3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

What Is The Driver Of The Alpha Mannosidosis Market?

The rising demand for precision medicine is expected to propel the growth of the alpha mannosidosis market. Precision medicine is a tailored approach to healthcare that considers individual differences in patients' genes, environments, and lifestyles to optimize treatment and prevention strategies. The rise in precision medicine is driven by advancements in genomic technologies and data analytics, which enable more accurate identification of genetic variations and their impact on health. Additionally, the increasing demand for personalized treatment options, alongside growing awareness of the limitations of one-size-fits-all approaches, has fueled interest in tailored healthcare solutions. Precision medicine enhances the development of targeted therapies tailored to the specific genetic mutations and patient profiles associated with this rare disorder. For instance, in February 2024, according to the data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization reported that in 2023 FDA approved 16 new personalized treatments for rare diseases, marking a substantial increase from just six approvals in 2022. Therefore, the rising demand for precision medicine is driving the growth of the alpha mannosidosis industry.

Key Players In The Global Alpha Mannosidosis Market

Major companies operating in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Zymenex A/S, Albumedix Ltd, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Herantis Pharma Plc, PTC Therapeutics, Biocad, Sanofi, Orchard Therapeutics, Shire Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical Inc, Genzyme

Global Alpha Mannosidosis Market Trends and Insights

Major companies operating in the alpha mannosidosis market are focusing on developing enzyme replacement therapy for rare alpha-mannosidosis. By supplying exogenous alpha-mannosidase, enzyme replacement therapy helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs. This accumulation is a characteristic feature of alpha-mannosidosis and contributes to the disease's pathological effects. For instance, in February 2023, Chiesi Global Rare Diseases a US-based pharmaceutical company launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for the treatment of alpha-mannosidosis, a rare genetic condition marked by an absence of the enzyme alpha-mannosidase in the body, and its manifestations outside of the central nervous system. Lamzede restores normal cellular activity in patients by acting in the same manner as the human body's alpha-mannosidase enzyme. Once a week, patients receive an injection of 10 mg of Lamzede.

What Are Latest Mergers And Acquisitions In The Alpha Mannosidosis Market?

In April 2023, Chiesi Farmaceutici an Italy-based pharmaceutical company acquired Amryt Pharma for $1.25 billion. The acquisition strengthens Chiesi’s Global Rare Diseases business division by adding Amryt Pharma’s approved commercial products for rare diseases to its portfolio of offerings. Amryt Pharma is a UK-based pharmaceutical company focused on developing and delivering innovative new treatments for rare diseases

Regional Insights

North America was the largest region in the alpha mannosidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Alpha Mannosidosis Market?

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alpha Mannosidosis Market Report 2026?

The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.